Ethnopharmacological relevance: In spite of the rich bio-cultural diversity found in the Neotropics relatively few herbal drugs native to South America are included in the global pharmacopoeia.
Introduction

Biodiversity and cultural diversity of Brazil
The American continent harbours around 125,000 native vascular plant species (Ulloa et al., 2017; Tropicos: http://www.tropicos.org/ Project/VPA) or 33% of the known 383,000 vascular plants species worldwide (Ulloa et al., 2017) . Particularly rich are the Neotropics with an estimated 90,000 to 110,000 plant species (Antonelli and Sanmartín, 2011) , half of which occur in the Amazon basin (Hubbell et al., 2008) . With up to 50,000 species, Brazil has the largest flora in the Neotropics (Lewinsohn and Prado, 2005; Shepherd, 2003; Ulloa et al., 2017) . Besides a rich biodiversity around 300 Amerindian groups (including ca. 900,000 individuals) associated with 274 different languages are living in Brazil (IBGE, 2019; survivalinternational.org) . Around 325,000 live now in urban and 570,000 in rural areas (ISA, 2019; IBGE, 2019) . 
Herbal drugs from the neotropics included in the European Pharmacopoeia
Although the different indigenous groups of Brazil and the Americas in general have a long standing tradition regarding the practice and understanding of herbal medicine and materia medica (e.g., Rodrigues, 2006; Odonne et al., 2013; Monigatti et al., 2013; van Andel et al., 2014; Bieski et al., 2015; Paniagua-Zambrana et al., 2015; Geck et al., 2016; Pedrollo et al., 2016 , Ribeiro et al., 2017 relatively few medicinal plants native to the Americas and specifically Brazil have been developed into globally important herbal medicines (Brandão et al., 2008; Heinrich et al., 2014; Dutra et al., 2016) . Currently, the European Pharmacopoeia (Ph. Eur. 9.5, 2017) includes 30 monographs treating 18 herbal drug aggregates native to Meso and South America 1 (see Fig. 1 , Table 1 and Supplementary Table A) . Several herbal drugs from the Neotropics were of historical importance in Europe and the USA but later excluded from pharmacopoeias and dispensatories. For example, the core wood of Guaiacum officinale L. (lignum vitae) was imported to Europe from the West Indies (Caribbean archipelago) as a cure for syphilis, but later found to be ineffective and thus abandoned (Waugh, 1982; Mann, 1984) . Other sudorific drugs such as the root of Sarsaparilla (Smilax spp.) from Mesoamerica (Felter and Lloyd, 1898) and lignum sassafras (Sassafras albidum (Nutt.) Nees) from North America were used as substituents for the ineffective G. officinale until it was realized that also these drugs were not effective (Munger, 1949) . Jalap root (also named 'root of Michoacán', mostly Ipomoea purga (Wender) Hayne but also including roots of other Ipomoea spp., see Pereda-Miranda et al. (2006) and Linares and Bye (1987) ) is described in the 'Codex de la Cruz Badiano' (Gates, 2000) as well as in the 'Historia Natural de Nueva España' (Hernández, 1959: II, 456) . This was imported to Europe as a substitute for Mediterranean purgatives such as scammony (Convolvulus scammonia L.) as early as 1610 (Castañeda-Gómez and Pereda-Miranda, 2011) . Jalap root was included in the commentary to the American pharmacopoeia, the Dispensatory of the United States (Wood and Bache, 1833) and still appeared in the 25th edition of the Dispensatory of the United States of America (Osol and Farrar, 1955) but later excluded. Also in Europe, jalap root was included in several important pharmacy books (e.g. Stocker, 1810; Bigelow, 1822; Felter and Lloyd, 1898) and was part of the Edinburgh New Dispensatory (Duncan, 1803) as well as the London Dispensatory (Thomson, 1826) . Jalap was also present in the German Pharmacopoeia from 1872 and 1926 among descriptions for preparations of drugs such as Tinctura Resinae Jalape, Tubera Jalapae, Resina Jalapae, Pilulae Jalapae and Sapo jalapinus, but excluded in the following versions (Eich, 2008) . The reason for excluding jalap root from the officinal materia medica was that even minimal overdosing may cause sever inflammations of the mucous membranes of the intestine and colon due to the resin glycosides, which are able to dissolve lecithin from the epithelial intestinal cells (Eich, 2008) . Another remarkable example is Quassia amara L., popularly known as 'Quinquina de Cayenne', which was widely used as a febrifuge and antimalarial drug in Europe, and included in some European pharmacopoeias such as the Pharmacopoeia of the Royal College of Physicians of London (Healde and Latham, 1793) and the Farmacopea Oficial Española, (6th edition from 1884) as well as in several important medical books (e.g., Gray, 1821; Christison, 1842; Felter and Lloyd, 1898; Cullen, 1789) . The extract and derivatives of Q. amara leaves have been proven active against malaria in vivo (Ajaiyeoba et al., 1999; Bertani et al., 2006) and the potent antimalarial and anticancer simalikalactone E has been patented, but accusations of biopiracy are hampering any further development into a pharmaceutical drug (see Bourdy et al. (2017) for a thorough discussion). Q. amara wood is mentioned in the British Herbal Pharmacopoeia from 1996, the British Herbal Compendium from 1992, the 32nd edition of Martindale (The Complete Drug Reference) and the second edition of the Physicians' Desk Reference for Herbal Medicine but it is not included in the Ph. Eur. 9.5 (2017) . Cascarilla stem bark, predominantly deriving from Croton eluteria (L.) W. Wright or Croton cascarilla (L.) L. (Evans et al., 2009) was much appreciated for its bitter and aromatic quality and used as a tonic stimulant, for treating fever, vomiting, dysentery and menorrhagia (Gray, 1821) . It was often combined with Cinchona sp. bark and generally prepared as an infusion (Thomson, 1862) but currently not included in the Ph. Eur. or the U.S. Pharmacopoeia (USP). Extracts of coca (Erythroxylon spp.) were included in the Farmacopea Oficial Española (Anonymous, 1884) as 'Vino de coca del Perú' and in Felter and Lloyd (1898) as 'Vinum Erythroxili' but today coca leaves are banned from being imported and sold in Europe and the US under the 'Single Convention on Narcotic Drugs' from 1961. Thus, pharmacopoeias and dispensatories are not static while the inclusion and persistence of (herbal) drugs in pharmaceutical compendia is related to their effectiveness and safety as well as dependent on political considerations.
Research question
In the attempt to explain the inclusion and exclusion of herbal drugs into pharmacopoeias we pursue the question as to why only few herbal drugs native to Meso-and South America, and specifically Brazil, are included in the Ph. Eur. 9.5 (2017) as well as in the current edition of the Brazilian Pharmacopoeia (2010) , notwithstanding the rich biocultural diversity of the Neotropics.
Methodology
Organization of the text
The article assumes a historical perspective using the different epidemiology and cultural evolution of the New (Americas) and the Old World (Eurasia and Africa) as a backdrop against which the development of herbal medicine and pharmacopoeias is projected. In section 4 we consider the epidemiological situation of pre-Columbian America and the relatively short interaction with Old World crowd diseases in the differential development of herbal medicine with respect to the Old World. With the help of existing literature we discuss the origin and purpose of pharmacopoeias and sketch the development of pharmacopoeias in Europe and the Western world (section 5) pointing out how newly discovered and occupied territories during the period of colonization and the search for efficacious medicines led to the inclusion of exotic herbal drugs and remedies. In sequence, the racial, economic and social forces working towards and against the process of homogenization of herbal pharmacopoeias are reviewed. In section 6 always based on the analysis of existing literature, we explain how early efforts in pharmacognosy and chemistry in Europe led to a preferential investigation and characterization of herbal medicines and chemicals included in the official European pharmacopoeias and generally of those herbal drugs widely used in Europe and thus commercially important, whether exotic or native.
In section 7 we finally sketch the development of the Brazilian Pharmacopoeia and compare the herbal drugs included in the latest version with those herbal drugs licenced by the 'Agência Nacional de Vigilância Sanitária do Brasil' (ANVISA database 2016, see Carvalho et al., 2018) and those included in a popular book entitled 'Plantas Medicinais no Brasil: Nativas e Exóticas' (Lorenzi and Matos, 2008) . We showcase how exotic species dominate the officinal and licenced products and highlight the untapped potential of traditional herbal medicine and biodiversity of Brazil.
Selection of references for comparison
'Plantas Medicinais no Brasil: Nativas e Exóticas' reflects a consensus about the most important medicinal plants used in traditional and folk herbal medicine across Brazil (Lorenzi and Matos, 2008 p. 5) and has not the pretention to be complete. It was chosen as a reference for this comparison because it is one of the few and better books on this subject for Brazil suiting the purpose. Alternatively the 6 vols. by Manuel Pio Correia entitled 'Dicionário das Plantas Úteis do Brasil e das Exóticas Cultivadas', published from 1926 onwards and containing approximately 10,000 species could have been used. However, Pio Correia (1926) does not follow a consensus approach of ethnobotanical uses and the taxonomy is outdated. .
Handling of monographs, herbal drug species and their geographic distribution
Herbal drug monographs in the European Pharmacopoeia 9.5 (2017) treating the same herbal drug species (e.g. Thymi herba and Thymi typo thymolo aetheroleum) were aggregated and counted as one, as well as alternative herbal drug species of the same genus included in one monograph (e.g. Salix purpurea L., S. daphnoides Vill., S. fragilis L.) and termed "herbal drug aggregates". The two monographs on Balsamum peruvianum (Myroxylon balsamum (L.) Harms var. perierae (Royle) Harms) and Balsamum tolutanum (Myroxylon balsamum (L.) Eur. 9.5 (2017) . The numbers before a '+' indicate the number of herbal aggregates deriving from that geographical unit while the numbers after a '+' indicate the number of herbal drug aggregates with a larger distribution area and occurring in the adjacent areas as well. The pie chart reading starts at 12:00 (Africa 4%). Supplementary Table A reports the native distribution for each herbal drug aggregate.
Table 1
The 219 herbal drug aggregates included in the Ph. Eur. 9.5 (2017) arranged by their native distribution.
Origin n Origin n et al., 1986-2012) were followed. As the geographical origin, especially that of cultivated taxa, is often not exactly known, we define 'native distribution' as the geographical distribution for which human activity is apparently not responsible. For cultivated plants we have followed the native distributions mentioned in Zohary and Hopf (2000) .
Epidemiology in the Old World and the New World and consensus about herbal medicines
Agriculture and animal husbandry evolved independently in various regions of the world but started first in the fertile-crescent in Mesopotamia (Zohary and Hopf, 2000; Diamond, 2002) . The Neolithic Demographic Transition together with animal husbandry in the Old World increased the probability of zoonotic pathogen transfer resulting in many human infectious crowd diseases such as measles, influenza, pertussis, diphtheria and smallpox (Diamond, 2002; Comas et al., 2013) . These viral and bacterial infections spread to humans from epidemic diseases endemic to domestic (herd) animals, and depend on dense host populations in order to sustain themselves (Diamond, 2002) . Also the altering dietary patterns and working habits emerging during the Neolithic revolution contributed to the changing epidemiology in the Old World. The greater health risk farmers were exposed to, therefore increased the interest in plants with medical values while, additionally, wild famine foods were important when the crop harvest failed. Brown (1985) pointed out that traditional agriculturalists distinguish generally more wild plant species than hunter-gatherers. Agriculturalists began to find their medicines among cultivated crops and wild food plants as well as the weedy flora adapted to the ecological niches created by their own activity (Logan and Dixon, 1994; Leonti et al., 2006) . Out of the 25 major infectious diseases responsible for the highest mortality and morbidity in human history an unambiguous New World origin could only be established for Chagas' disease (Wolfe et al., 2007) . For syphilis the situation remains unclear and the debate about its origin is ongoing (Wolfe et al., 2007) but historical data point towards a New World origin (Waugh, 1982; Mann, 1984, p. 215) . There is supporting evidence that human tuberculosis originated in Africa over 70,000 years ago (Comas et al., 2013) yet the current Mycobacterium tuberculosis strains of the Americas are closely related to European strains (Bos et al., 2014) . The analysis of M. tuberculosis genome found in pre-Columbian mummies suggests a zoonotic transfer from pinnipeds around 700 to 1000 CE, which presumably contracted M. tuberculosis from an African host and transferred the germs to South America (Bos et al., 2014) . This would be compatible with the occurrence of pre-Columbian skeletal lesions attributed to M. tuberculosis infections (Bos et al., 2014) . No data supporting any conclusion regarding their geographical origin are available for rotavirus, rubella, tetanus and typhus while for the other 18 pathogens an Old Word origin is almost certain (Wolfe et al., 2007) . In contrast, agriculturalists and hunter-gatherers in the New World had to deal with fewer infectious diseases before the European Conquest, due to limited domestication of herd animals. Epidemiological data further suggest that Amerindian populations generally suffer a higher incidence of gastrointestinal problems, such as bile acid metabolism disorder, gallstone diseases, biliary tract and gallbladder cancer (Michaud, 2002; Shaffer, 2006) . On top of that has the adoption of a westernized diet and life-style by Amerindian populations resulted in an increase in the prevalence of diabetes, obesity, hypertension and dyslipidemia and augmented the probability for contracting cardiovascular complications such as atherosclerosis and stroke (Broussard et al., 1991; Galloway, 2002) . This seems to be associated with genes permitting an effective food metabolism (the so called "thrifty" genes), which are important for survival in nutritionally less predictable environments but become a risk factor when food becomes affluent (Hanis et al., 1986; Diamond, 2003) . As a consequence, pre-Columbian traditional medicine is and was shaped by a different epidemiological context when compared to Old World medicine.
Moreover, the lack of written languages [the few surviving Maya codices are an exception] hampered the building of a large consensus about efficacious pre-Columbian medicines and reduced the possibility for cumulative knowledge transmission (see Lewis and Laland, 2012; for concept and mechanisms). Today some of the most widely used herbal remedies in rural areas and by indigenous groups in northern South America are introduced from Eurasia, Africa, North America and the Pacific (Bennett and Prance, 2000 ; see also Lorenzi and Matos, 2008) . Although Leishmaniasis is endemic and native to tropical South America, for instance, many of the most frequently reported remedies from a cross-cultural analysis of 291 herbal species (Odonne et al., 2017) are cultivated or/and exotic.
It is, however, highly likely that, due to their more isolated subsistence, indigenous Amerindian groups show a much higher idiosyncrasy of native medicinal plant use (see e.g., Prance, 1973; Schultes and Raffauf, 1990; Milliken and Albert, 1996; Doyle, n.d.) . During the last decades however, only few field studies have been conducted with indigenous Amerindian groups living in the Brazilian Amazon. This might be attributable to logistic issues and difficulties in obtaining permission from government agencies such as the FUNAI (Fundação Nacional do Índio) and the MMA (Ministério do Meio Ambiente).
Development of pharmacopoeias with a focus on Europe
Origin and purpose of pharmacopoeias and the inclusion of exotic drugs
Pharmacopoeias have their origin in local, regional and over-regional consensus collections of therapeutic knowledge about remedies derived from plant, animal, fungal and mineral origin. Such texts were called materia medica, then compositiones medicamentorum, antidotarii or dispensatorii, later on 'herbals' and finally 'pharmacopoeias' (Urdang, 1951) and testify to the early inclusion of exotic herbal drugs (Heffter, 1914) . The first texts reproducing knowledge on materia medica (e.g., Ebers papyrus (ca. 16th century BCE, Egypt), Corpus Hippocraticum (Hippocrates and allies, 600-200 BCE, Greece), 'Enquiry into Plants' (Theophrastus, ca. 370-285 BCE, Greece), De Materia Medica (Dioscorides, 1st century CE, Greece), 'Shennong Bencaojing' (The Classic of Herbal Medicine, ca. 200-245 CE, China), the 'Bower Manuscript' (by Buddhist monks, ca. 600 CE, India)) were compiled on the perceived consensus of the therapeutic and commercial importance of the drugs used in a certain geographical area, and intended as a reference standard for medical doctors and their aspirants as well as those selling and compounding medicines (Urdang, 1951; Unschuld, 1986; Heinrich et al., 2004; Leonti and Verpoorte, 2017) .
Today, the armamentarium of drug treatment is transmitted through 'pharmacopoeias', which are standard publications regulating the quality of pharmaceutical drugs, excipients and flavouring correctives, specifying their testing methods, purity, storage instructions, composition and concentration. Pharmacopoeias secure the uniformity of remedies approved by representatives of a specific political unit and make the quality standards obligatory (Urdang, 1951, p. 583) . The usefulness of a pharmacopoeia (literally 'drug making') is "determined by the periodical changes it has to undergo to keep pace with the latest progress in the sciences on which it is based" (Urdang, 1951, p. 577) . With respect to herbals, pharmacopoeias are distinguished in that they are legally binding quality standards and do not include therapeutic recommendations. This legally binding character has an imminent impact on the continuity of drug use. The pharmacopoeia of the city of Florence (Florentine 'Nuovo Receptario') from 1498 is regarded as the first official pharmacopoeia (Urdang, 1951; Corradi, 1966) . Among the first true official state pharmacopoeias are the 'Ricettario Fiorentino' from 1573 (Grand Duchy of Tuscany) and the Pharmacopoeia Londinensis from 1618 (Realme of England) (Urdang, 1951) .
In any event, the development of official pharmacopoeias was strongly influenced by the separation of medicine from pharmacy, a functioning public welfare system and the idea that the state is responsible for the health of its citizens (Urdang, 1951) . A crucial step for the development of the European pharmacopoeias was the integration of indigenous drugs "discovered" during the colonial expansions of European kingdoms (e.g., Heffter, 1914, p. 16 Mann, 1984; Giorgetti et al., 2007; Brandão et al., 2012; Breitbach et al., 2013; Heinrich et al., 2014; Helmstädter, 2017; Leonti and Verpoorte, 2017; Rivera et al., 2017; Ricardo et al., 2018) . This development culminated in the (transient) wealth of many European city-states depending on the herbal drug and spice trade (Tschirch, 1910) . Moreover, from the 16th century onwards, herbal drugs have been cultivated wherever geographical, climatic and ecologic conditions allowed for economic production (Tschirch, 1910) . Frequently the cultivations far from their native habitats were more productive as the pests and diseases were left behind (Prance, 2005 p. 28 ).
The many new herbal drugs and exotic plant species that arrived from overseas led to a rekindled interest in systematic botany and the attempt to systematize and assess the various herbal drugs used in folkmedicine in Europe and introduce them in medicine (Heffter, 1914 p. 16-17) .
Racial, nationalistic and economic considerations affecting the homogenization of pharmacopoeias
Notwithstanding the increasing globalization and the synchronization of pharmacopoeias, which finally led to the European as well as the International Pharmacopoeia, the process was characterized by racial and political considerations as well as erroneous beliefs. According to Urdang (1951) "in earlier days … it was thought that drugs originating in a certain country had an especially beneficial relation to the bodies of the residents of their common habitat" (Urdang, 1951, p. 583) , which is also reflected in the introduction of the Pharmacopoeia Londinensis from 1618, which reads: "Why should not the citizens of London have their own? [Pharmacopoeia] … the appreciation of which does not arise so much from its being precious, but from its being appropriate and welladapted to English bodies" (Urdang, 1951, p. 584) . According to Heffter (1914, p. 17) already at the beginning of the 16th century in Germany and France the idea circulated that those plants, which grew underneath the hot sun would not be salubrious to inhabitants of the temperate zone while Paracelsus (1493-1541) as well as Tabernaemontanus (1522-1590) thought that plants growing in a type of land and air are most beneficial to those, who were born and live there (Heffter, 1914, p. 17) .
Similar ideas can still be found in recent articles, for example that by Pandalis and Keil (2014, p. 75) , stating that "the concept explains why medications, which are proven for centuries are essential for healthbut exclusively within their respective ethno-context". This not only reminds us of gene polymorphism responsible for drug metabolism, but also of the concept of 'local biologies', referring to the fact that human biology shows universal and local characteristics (Niewöhner and Lock, 2018) . A similar idea was the belief that the geographic origin of a disease would coincide with the origin of effective drugs (Mann, 1984) . This makes sense in the light of a long bio-cultural interaction, i.e. a local trial and error approach to find appropriate drugs. Another factor that prevented the homogenization of pharmacopoeias were nationalistic ideologies and economic considerations leading to preferential inclusion of locally sourced and produced drugs on the expense of exotic drugs (Urdang, 1951 ). Urdang's (1951, p. 596) idealistic view of pharmacy is that in a similar fashion to medicine it is "an organized human attempt to meet elementary human needs not restricted to nationality, creed, or environment" and therefore "by its very nature international". Similarly, Tschirch (2015, p. 22 ) noted in 1909, that "we don't ask anymore where a remedy is coming from but if it's effective".
Giving way to the pressure of global trade, can however, have an immediate impact on the inclusion of materia medica as the document A4-0075/97 by the European Parliament testifies: "The European Pharmacopoeia, as drawn up by the Council of Europe, needs to be opened up to other pharmacopoeiae particularly the medicinal plants used in Chinese medicine" (Bauer and Franz, 2010) . Herbal drugs from other regions of the world, such as Ayurvedic or South American medicines, were not considered in this working programme (Bauer and Franz, 2010) .
Inclusion of exotic herbal drug monographs in Ph. Eur. 9.5
Currently 219 herbal drug aggregates are listed in the Ph. Eur. 9.5 (2017), of which 97 (44%) are native to Europe (and adjacent territories; sum of rows L-X in Table 1 ) and only 12 are from South America, four from Mesoamerica while two have a pantropic distribution (Fig. 1) . As much as 81% (178; sum of rows G-J + sum of rows L-X in Table 1 ) of the herbal drug aggregates included in the Ph. Eur. 9.5 (2017) are native to Eurasia. The many Chinese herbal drug aggregates (ca. 30, of which currently 17 without an entry in the European Medicines Agency), which were continuously included beginning with Ph. Eur. 6 (Bauer and Franz, 2010 ) certainly contribute to this high share (see supplementary Table A ). There is, however, also evidence pointing towards a more historical and geographical component regarding the inclusion of herbal drugs native to Eurasia: The vastness and the geographical extension (East-West axis) of Eurasia, with its almost identical day-lengths, seasons, climates, habitats and diseases, facilitated the successful exchange of a high diversity of useful germplasm, including that of herbal medicines, spices and food plants (e.g. Allium sativum, Brassica napus, Trigonella foenum-graecum, Coriandrum sativum, Triticum aestivum, Sesamum indicum, Carthamus tinctorius, Linum usitatissimum; see supplementary Table A ). The North-South axis of the Americas in contrast worked as a factor complicating the exchange of valuable herbal species (see Diamond, 2002 for a more general discussion on this issue). This is also supported by the so-called Rapoport's rule asserting that while higher latitude species show larger geographical-range size, lower latitudes support more species (Stevens, 1989 ; and see Leonti et al., 2013 p. 102-103 for discussion related to plants used as medicine). The favourable conditions for exchanging germplasm of proven herbal drugs and spices as well as for commercializing herbal drugs across Eurasian cultures since ancient times facilitated therapeutic experimentations, the diversification of uses and the inclusion of 'exotic' drugs into local medicinal floras and pharmacopoeias. This historical D. Tabajara de Oliveira Martins, et al. Journal of Ethnopharmacology 240 (2019) 111891 legacy, deriving from the consensus around local medicinal systems across Eurasia and Northern Africa is also reflected in the Ph. Eur. 9.5 (2017).
The contribution of pharmacognosy to the development of pharmacopoeias
In a collaborative effort, during the 19th century, French and German chemists, physiologists and naturalists such as Alexander von Humboldt (1769-1859), Friedrich Sertürner (1783-1841), Joseph Pelletier (1788-1842), Claude Bernard (1813-1888), and others, conducted ethnopharmacological field studies, isolated pure active compounds and described their pharmacological effects (Bruneton, 1995, pp. 625-642; Heinrich et al., 2004; Gertsch, 2009 ). The coordinated interdisciplinary scientific investigations provided the necessary pharmacological and toxicological basis for the inclusion of pure chemical entities into the official pharmacopoeias (Heinrich et al., 2004; Wagner et al., 2007; Gertsch, 2009 , and see also the different official pharmacopoeias). This development changed the character and composition of the pharmacopoeias. While, for example, the first German pharmacopoeia from 1872 contained 255 herbal drugs, the 5th edition from 1910 included only 167. In parallel the presence of chemical preparations increased from 53 in 1872 to 98 in 1910 (Heffter, 1914, p. 33) . During the 19th and early 20th century pharmacognosy flourished in Germany (Heinrich and Anagnostou, 2017) resulting in innovative literature mostly published in German, which contextualized history of ethnomedicine with the latest discoveries in chemistry and pharmacology (e.g., Köhler, 1887; Lewin, 1894; Hartwich, 1897; Tschirch, 1909 Tschirch, -1925 . Similarly, the advancement of organic and natural product chemistry was mainly published in German during the 19th century (e.g., Liebig, 1837; Liebig und Geiger, 1843; von Hofmann, 1843; Kolbe, 1874; Baeyer, 1878) . The chemical, pharmacological and toxicological characterization of the herbal drugs included in the European pharmacopoeias as well as the main medicinal plants used in Europe was still a major task of European pharmacognosists during the 1970s to the 1990s. As language is the main key in knowledge transmission, the instant access to the progresses in chemistry resulted in a strategic advantage of German-speaking scientists. Together with the establishment of scientific schools focusing on pharmacognosy and chemistry, and according to the principles of cultural evolution and knowledge transmission (see e.g. Cavalli-Sforza and Feldman, 1981; Diamond, 2005; Richerson and Christiansen, 2013) , this allowed for a head start in central Europe and is part of the reason why the pharmaceutical (including those producing plant based medicines and nutraceuticals) and chemical industry is so well established in this European region still today (e.g. Novartis, Hoffman-La-Roche, Merck Serono, Clariant, Ciba, Lonza, DSM, Henkel, Hoechst, BASF, Bayer, Schwabe, Weleda).
Development of the Brazilian Pharmacopoeia, herbal products registered with ANVISA and plants used in popular and traditional medicine
Development of the Brazilian Pharmacopoeia
The Historia Naturalis Brasiliae written by the Dutch physician Willem Piso (1610-1678) and the German naturalist Georg Marcgraf (1610-1644) is the first scientific work about the natural world and traditional medical knowledge from Brazil (Françozo, 2010) . The first pharmaceutical codex applied in colonial Brazil was, however, the 'General Pharmacopoeia for the Kingdom and Domains of Portugal' ('Farmacopeia Geral para o Reino e os Domínios de Portugal') by A. Tavares from 1794, and obligatory in Brazil from 1809 onwards. After gaining independence (1822), in addition, the French 'Codex Medicamentarius' (compulsory from 1851 onwards) was used by pharmacists. In 1882 it was established that the French Pharmacopoeia should be followed for the preparation of remedies, until the publication of the first Brazilian Pharmacopoeia, which saw light in 1929 (Pianetti, 2016) . There exist five editions of the Brazilian Official Pharmacopoeia (FBRAS). The first was sanctioned in 1926 and published in 1929 ('Brazilian Pharmacopoeia Code -Pharmacopoeia of the United States of Brazil') while the current edition was published in 2010 replacing the previous 4 editions, which were all valid to this date (Pianetti, 2016) . The initial adoption of European pharmacopoeias for sure consolidated the importance of exotic herbal drugs while the adoption of the French Pharmacopoeia appears like an attempt to shed off the colonial identity.
Herbal drug monographs in the Brazilian Pharmacopoeia and the presence of exotic species
In all its editions, the Brazilian Pharmacopoeia contained more exotic than native herbal drug species (Brandão et al., 2006; ANVISA, 2010) . In parallel to the replacement of 'boticas' (herbal dispensatories) by pharmacies (drugstores) in succession of the isolation and synthesis of pure pharmaceutical compounds, the number of herbal drug monographs was drastically reduced in the first three editions of the Brazilian Pharmacopoeia (Brandão et al., 2006, Table 2 ). The share of native herbal drug monographs included in the Brazilian Pharmacopoeia has dropped from an initial 27.5% in 1929 to 15.6 and 17.4% in 1959 and 1977, respectively, but more recently (ANVISA, 2010, 5th edition) increased again to 26.9% corresponding to 15 species (Table 2 ; Fig. 2,  supplementary table B) .
The current fifth edition of the Brazilian Pharmacopoeia (ANVISA, 2010 "Farmacopoeia Brasileira, Vol. 2, Monografias 5 a edição") comprises only 55 herbal drug aggregates (see Table 3 ). The 359 herbal medicinal products licensed in Brazil contain herbal drugs derived from 101 different species (Carvalho et al., 2018) . Of these "eight are native endemic, 19 are native non-endemic, six are naturalized, six are cultivated, and 62 are not originated in Brazil" (Carvalho et al., 2018) . Since those cultivated and naturalized species are all exotic to Brazil of the 101 species, only 27 are native (27%). Thus herbal drug species of products registered with ANVISA and those included in the Brazilian Pharmacopoeia are for the larger part exotic to Brazil (Table 3; Figs. 2 and 3). This was partially explained with the better documentations of efficacy and safety, as well as existing quality standard requirements and control protocols for non-native herbal drugs (Carvalho et al., 2018) . Thus, currently, and in spite of the higher biodiversity of Brazil with respect to Europe, the Brazilian Pharmacopoeia includes a considerably lower share of native species (ca. 27%) when compared to the European Pharmacopoeia (44%) (Figs. 1 and 2, Tables 1-3 ) and the number of licenced herbal medicines is relatively small when compared internationally (Carvalho et al., 2018) .
Currently, among the 20 best-selling herbal medicines in Brazil, only one product derives from a species (Cordia curassavica (Jacq.) Roem. & Schult., syn. Cordia verbenacea A.DC.) native to Brazil (Dutra et al., 2016) and among the 12 herbal medicines available through the public health care system in Brazil, 8 were developed from exotic plant species. These data are a reflection of the Brazilian herbal and Martins, et al. Journal of Ethnopharmacology 240 (2019) 111891 phytotherapeutic policies (BRASIL, 2006a (BRASIL, , 2006b , notwithstanding that these claim "… it prioritizes the biodiversity of the country [Brazil] …". Of the five main lists of medicinal plant species 2 formulated by Brazilian government agencies aiming at encouraging the utilization, study and development of herbal medicines around 65% are exotic (supplementary Table C ). In line with these official documents, the 263 research groups working with medicinal plants (CNPq, 2018) and the pharmaceutical laboratories of Brazil developing herbal medicines pay little attention to native species of Brazil. With the new patent law adopted in Brazil in 1996, an increase in the number of herbal medicines deriving from the Brazilian flora was expected but the registration process was afflicted with inefficiency and bureaucratic issues (Hasenclever et al., 2017) . With the legalization of generic drugs in Brazil in 1999 the pharmaceutical industry concentrated their investments in the production and commercialization of generic drugs (Pontes, 2017) . That only few native species are used for the production of herbal medicinal products in Brazil might also be associated with the restrictive framework regulating access to biodiversity from 2001 (Carvalho et al., 2018) . The new law (n°13,123, May 2015) regulates research with biodiversity in Brazil as well as the access and protections of associated traditional knowledge in a more transparent way specifying benefit-sharing mechanisms. Moreover, in a process aligning the Brazilian legislation with international standards, next to "herbal medicines", for which clinical and non-clinical trials are mandatory for registration, now also "traditional herbal products" are distinguished, for which the documented traditional use (at least 30 years) is regarded as a proxy for safety and effectiveness (Carvalho et al., 2018) . This simplification for licencing herbal medicinal products is expected to lead to new registrations making use of local traditional herbal practices.
For example, of the 335 plant species presented in the book 'Plantas Medicinais no Brasil' by Lorenzi and Matos (2008) 135 are exotic and 200 (60%) are native. In total 177 native species, which are referenced by Lorenzi and Matos (2008) and used in traditional and folk medicine in Brazil, are neither part of licenced products nor included in the Brazilian Pharmacopoeia (Fig. 3) . Only 12 herbal drug species (4 of them native) are simultaneously contained in the Brazilian Pharmacopoeia, present among the herbal medicinal products licensed and included in the book by Lorenzi and Matos (2008;  Fig. 3, Table 3 ). As many ethnopharmacological field studies have shown, the herbal knowledge of people and communities in Brazil exceeds by far the herbal knowledge described in Lorenzi and Matos (2008) .
Conclusions
Notwithstanding the higher biodiversity of Brazil with respect to Europe, the Brazilian Pharmacopoeia includes a considerably lower share of native herbal drugs when compared to the European Pharmacopoeia. We associate this discrepancy to several factors linked with biogeographic preconditions, disparate historical developments of medicine and pharmacy as well as cultural evolution at large. Accumulated evidence suggests that at the time of the Conquest the epidemiology of the Amerindian populations resembled more that of pre-agriculturalist societies, while no written consensus around efficacious medicine existed. The trial and error approach using biodiversity for the treatment of infections and symptoms associated with crowd diseases seems to have begun in the Americas only after the Conquest. Consequently, the time local medicines in the New World were empirically tested for the treatment of these frequent afflictions was inferior when compared to Eurasia and Africa. The East-West orientation of Eurasia facilitated the successful exchange of germplasm of welltried plant species over wide areas and the building of a consensus around efficacious medicine. On the other hand did the high species richness in the Neotropics together with the lack of written languages aggravate the exchange and conservation of knowledge. After the Table 3 Herbal species mentioned in the 5th edition of the Brazilian Pharmacopoeia (2010) , herbal species present in products registered with ANVISA (A) and herbal species popularly used as medicine in Brazil according to Lorenzi and Matos (2008; L N: Native to Brazil; E: Exotic to Brazil; A: ANVISA (Carvalho et al., 2018) ; L: Lorenzi and Matos (2008) .
D. Tabajara de Oliveira Martins, et al. Journal of Ethnopharmacology 240 (2019) 111891 colonization of the New World introduced and proven plant species empirically tested over millennia in the Old World gained therapeutic importance in the New World. Meanwhile the longstanding and cumulative pharmacognostic research activities in Europe and the USA focusing on the herbal drugs important in their pharmacopoeias resulted in an accumulation of herbal drugs with the status as safe and efficacious persisting in pharmacopoeias. The ethnopharmacological field studies conducted in the Neotropics are useful for highlighting consensus around the use of herbal medicines but seem to not have been able to include much data from Amerindian communities living in the Amazon in the past decades. This results often in studies lacking novelty reporting common herbal drug species, whether native or introduced. After the boom of the pharmaceutical industry resulting from the legalization of generic drugs, herbal medicinal products deriving from local biodiversity could represent timely and innovative products for investing the generated profits. Newly adopted regulations regarding access to biodiversity and traditional knowledge as well as the simplified procedure for licencing herbal medicinal products in Brazil prospects an interesting future for ethnopharmacologists and those aiming at developing herbal medicine based on bio-cultural diversity. Fig. 3 . Overlap between the herbal species included in the Brazilian pharmacopoeia, those used for products registered with ANVISA (see Carvalho et al., 2018) and those mentioned in Lorenzi and Matos (2008) . N = Native; E = Exotic. The numbers within the doted circles refer to taxa not included in the other 2 sources, respectively.
